


Rescue of MYH7 in
treating Hypertrophic
Cardiomyopathy with a
novel base editor system


Alexandra Badea, Alessandra Grosso, Rebecca
Reali, Kimia Rezairad, Eleonora Serra



What is Hypertrophic Cardiomyopathy?

- **Autosomal dominant disease** affecting 1/500 individuals
- Caused by mutations in sarcomeric genes, especially in **MYH7** and **MYBPC3**
- **Hallmarks:** hypertrophy of the left ventricle, cardiomyocytes disarray, fibrosis, hypercontractility and reduced compliance
- **Symptoms:** age-dependent and ranging from slight arrhythmias to sudden death

Normal heart



Hypertrophic Cardiomyopathy





Image created with biorender

The cardiac muscle myosin motor domain





The ATPase cycle



Which are the effects of R723G mutation?


- Severe form of HCM
- Altered movement of the lever arm
- Muscle degeneration
- Fiber stiffness
- Removal of a charged residue crucial for the stabilization of the top loop conformation




Aim of the project

Correct the R723G point mutation directly on the genomic DNA to restore the wt phenotype.

c: R723G mutation



d: Wild Type




Decreases the compliance of the interface

Fig. c,d: Robert-Paganin, J., Auguin, D. & Houdusse, A. Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition. *Nat Commun* 9, 4019 (2018). <https://doi.org/10.1038/s41467-018-06191-4>

CGBE1

a recently developed base editor
that allows C:G to G:C base
transversions




Components:




- RNA-guided Cas9 D10A nickase
- E. coli-derived uracil DNA N-glycosylase
- rat APOBEC1 cytidine deaminase variant (R33A)

How to fit a large base editor into the limited size of AAV?

Development of split-intein CGBE1 encoded into dual-AAV particles to bypass packaging size limit of <5 kb of AAV.



Split-intein CGBE1 dual-AAV9





sgRNAs were designed using CHOPCHOP web tool:


5' CCTGAGGAGGGAAGTGTCCAGAG 3'

5' CAGGATGCGATACCTGAGGAGGG 3'

5' TTCAGGATGCGATACCTGAGGAGGGAAGTGT 3'




In vitro experimental plan




In vitro results


Transduction efficiency




Cytotoxicity





Sanger sequencing at the target codon (723)




Base editing efficiency by getPCR



Analysis of off-target DNA and RNA editing




Relative expression of MYH7 mRNA per GAPDH by qPCR




In vitro results


Hypertrophy analysis by bright-field imaging




Sarcomeric disarray



Nucleation analysis (red arrows indicate multinucleated cells)




Hypertrophic marker BNP




In vitro results


Mitochondrial respiration and content by Seahorse platform and qPCR






Force measurements



Calcium handling analysis




In vivo experimental plan




- AAV distribution
 - Immunohistochemistry
- Base editing efficiency
 - getPCR
- DNA and RNA off-target and bystander edits
 - Whole genome sequencing
 - RNA-seq
- Expression levels
 - Western blot
- Morphological and functional assays
 - Histopathology
 - Contractility assay
 - Ecocardiography
 - Electrophysiology

In vivo results


Base editing efficiency by getPCR




Sanger sequencing at the target codon (723)




Analysis of off-target DNA and RNA editing




Ecocardiography



Electrophysiology




Relative expression of MYH7 mRNA per GAPDH by qPCR





In vivo results


Histopathological analysis of porcine cardiac tissue



Morphological analysis




Pitfalls and solutions



Budget

REF	Headings	Costs (\$)	
1. eligible direct costs			
A	Personnel: Researcher salary	35000\$ per year; x5: 175,000\$	
B	Equipment:	<ul style="list-style-type: none"> - WT Swine: 550\$ per animal (28 days of age) x5 = 2,750\$ - Genetically modified Swine: 2,250.00\$ per animal (28 days of age) x5 = 11,250 \$ 	
2. eligible indirect costs			
C	Supplier Tooling:	GET-PCR Kit: 130\$	Cell Viability: 300\$
		Western Blot: 2,000\$	Echocardiogram: 1,600\$
		AAV9 Vectors: 4,000 \$ x 2 = 4,000\$	Electrophysiology: 4,000\$
		Immunofluorescence Staining Kit: 90\$	RNASEq Oxford Nanopore:: 300\$
		Immunohistochemistry: 290\$	Cell Contraction Assay: 475\$
		Illumina Whole genome Seq: 200\$	Targeted deep DNA Seq: 350\$
		Sanger Seq Kit: 600\$	
Total: 1+2 = 189,000\$ + 14,335\$ = 203,335\$ per year			



Thank you for your attention

Bibliography

- Montag J, Petersen B, Flögel AK, Becker E, Lucas-Hahn A, Cost GJ, Mühlfeld C, Kraft T, Niemann H, Brenner B. Successful knock-in of Hypertrophic Cardiomyopathy-mutation R723G into the MYH7 gene mimics HCM pathology in pigs. *Sci Rep*. 2018 Mar 19;8(1):4786. doi: 10.1038/s41598-018-22936-z. PMID: 29555974; PMCID: PMC5859159.
- Robert-Paganin, J., Auguin, D. & Houdusse, A. Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition. *Nat Commun* 9, 4019 (2018).
- Kurt IC, Zhou R, Iyer S, Garcia SP, Miller BR, Langner LM, Grünewald J, Joung JK. CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells. *Nat Biotechnol*. 2021 Jan;39(1):41-46. doi: 10.1038/s41587-020-0609-x. Epub 2020 Jul 20. PMID: 32690971; PMCID: PMC7854778.
- Levy JM, Yeh WH, Pendse N, Davis JR, Hennessey E, Butcher R, Koblan LW, Comander J, Liu Q, Liu DR. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. *Nat Biomed Eng*. 2020 Jan;4(1):97-110. doi: 10.1038/s41551-019-0501-5. Epub 2020 Jan 14. PMID: 31937940; PMCID: PMC6980783.
- Zhang H, Zhan Q, Huang B, Wang Y, Wang X. AAV-mediated gene therapy: Advancing cardiovascular disease treatment. *Front Cardiovasc Med*. 2022 Aug 19;9:952755. doi: 10.3389/fcvm.2022.952755. PMID: 36061546; PMCID: PMC9437345
- Ai J, He Y, Zheng M, Wen Y, Zhang H, Huang F, Zhu Y. Characterization of Recombinant Adeno-Associated Viral Transduction and Safety Profiles in Cardiomyocytes. *Cell Physiol Biochem*. 2018;48(5):1894-1900. doi: 10.1159/000492510. Epub 2018 Aug 9. PMID: 30092576.
- Li B, Ren N, Yang L, Liu J, Huang Q. A qPCR method for genome editing efficiency determination and single-cell clone screening in human cells. *Sci Rep*. 2019 Dec 11;9(1):18877. doi: 10.1038/s41598-019-55463-6. PMID: 31827197; PMCID: PMC6906436.
- Querdel E, Reinsch M, Castro L, Köse D, Bähr A, Reich S, Geertz B, Ulmer B, Schulze M, Lemoine MD, Krause T, Lemme M, Sani J, Shibamiya A, Stüdemann T, Köhne M, Bibra CV, Hornaschewitz N, Pecha S, Nejehsie Y, Mannhardt I, Christ T, Reichenspurner H, Hansen A, Klymiuk N, Krane M, Kupatt C, Eschenhagen T, Weinberger F. Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Dependent Manner. *Circulation*. 2021 May 18;143(20):1991-2006. doi: 10.1161/CIRCULATIONAHA.120.047904. Epub 2021 Mar 2. Erratum in: *Circulation*. 2021 May 18;143(20):e979. PMID: 33648345; PMCID: PMC8126500.
- Billig S, Zayat R, Ebeling A, Steffen H, Nix C, Hatam N, Schnöring H, Derwall M. Transesophageal echocardiography in swine: evaluation of left and right ventricular structure, function and myocardial work. *Int J Cardiovasc Imaging*. 2021 Mar;37(3):835-846. doi: 10.1007/s10554-020-02053-7. Epub 2020 Oct 13. PMID: 33048268; PMCID: PMC7969559.
- Clauss S, Schüttler D, Bleyer C, Vlcek J, Shakarami M, Tomsits P, et al. (2020) Characterization of a porcine model of atrial arrhythmogenicity in the context of ischaemic heart failure. *PLoS ONE* 15(5): e0232374. <https://doi.org/10.1371/journal.pone.0232374>
- Hsieh J, Becklin KL, Givens S, Komosa ER, Lloréns JEA, Kamdar F, Moriarity BS, Webber BR, Singh BN, Ogle BM. Myosin Heavy Chain Converter Domain Mutations Drive Early-Stage Changes in Extracellular Matrix Dynamics in Hypertrophic Cardiomyopathy. *Front Cell Dev Biol*. 2022 Jun 16;10:894635. doi: 10.3389/fcell.2022.894635. PMID: 35784482; PMCID: PMC9245526.